Head of behavioral pharmacology and preclinical imaging, F. Hoffmann-La Roche
Here’s how Spooren describes what he will discuss in this webinar:
In this webinar, I will present the latest developments in Europe in the field of autism research centered around a consortium called European Autism Intervention – A Multicentre Study for Developing New Medications, or EU-AIMS.
Around 1 percent of children are diagnosed with autism, and yet there are no drugs available to treat the condition’s core features. EU-AIMS scientists are working to change this. One goal of EU-AIMS is to generate biomarkers that will allow us to better stratify individuals with autism and enhance our understanding of the condition. We hope to pave the way for the development of safe and effective treatments for autism in both children and adults.
The project’s scientists have created a large autism database. It is one of the richest of its kind in the world, and has the potential to drastically expand the knowledge base for autism.
I will also talk about the follow-up project to EU-AIMS, Aims2Trials, which includes a large clinical network designed to facilitate large clinical studies across Europe.